Long acting GLP-1 receptor agonist (injectable)

Semaglutide 0.4 mg injection once daily

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

SEMA_SC_0p4MG_QD

Mechanism: GLP-1 receptor agonist; daily or weekly (liraglutide; dulaglutide; semaglutide; exenatide extended release; albiglutide; efpeglenatide; loxenatide; taspoglutide and others)
Trials: 2
Participants in these arms: 116

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Overweight or obesity without diabetes (adults)	Systolic blood pressure change	weeks 40 to 104 (target week 68)	Placebo	MD -6.58 (-10.84 to -2.42)	0.80
Overweight or obesity without diabetes (adults)	Percent body weight change	weeks 40 to 104 (target week 68)	Placebo	MD -12.57 (-15.91 to -9.09)	0.85
Overweight or obesity without diabetes (adults)	SF-36 physical component summary change	weeks 20 to 130 (target week 52)	Placebo	MD 3.82 (0.70 to 7.28)	0.88
Overweight or obesity without diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 1.72 (0.76 to 4.06)	0.36
Overweight or obesity without diabetes (adults)	Nausea	longest follow-up	Placebo	HR 3.90 (2.57 to 5.94)	0.45
Overweight or obesity without diabetes (adults)	Vomiting	longest follow-up	Placebo	HR 5.90 (2.97 to 11.82)	0.37
Overweight or obesity without diabetes (adults)	Diarrhea	longest follow-up	Placebo	HR 2.28 (1.29 to 4.06)	0.42
Overweight or obesity without diabetes (adults)	Constipation	longest follow-up	Placebo	HR 3.65 (1.80 to 7.59)	0.25
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Serious adverse events	longest follow-up	Placebo	HR 1.37 (0.51 to 3.58)	0.44
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Discontinuation due to adverse events	longest follow-up	Placebo	HR 2.62 (0.11 to 89.90)	0.37
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Nausea	longest follow-up	Placebo	HR 3.84 (1.51 to 9.26)	0.36
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Vomiting	longest follow-up	Placebo	HR 7.18 (1.91 to 29.21)	0.37
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Diarrhea	longest follow-up	Placebo	HR 1.34 (0.56 to 3.06)	0.65
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Constipation	longest follow-up	Placebo	HR 2.29 (0.93 to 6.28)	0.39
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Discontinuation due to gastrointestinal adverse events	longest follow-up	Placebo	HR 2.54 (0.25 to 27.15)	0.45
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Resolution of steatohepatitis without worsening of fibrosis	weeks 48 to 104 (target week 72)	Placebo	OR 5.89 (1.22 to 20.06)	0.92
Metabolic dysfunction associated steatotic liver disease or steatohepatitis	Fibrosis improvement without worsening of steatohepatitis	weeks 48 to 104 (target week 72)	Placebo	OR 1.48 (0.42 to 4.84)	0.70

Semaglutide 0.4 mg injection once daily

Related

Effects across outcomes

Trials